Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ABCF2 CRISPR/Cas9 KO Plasmid (h): sc-406271
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ABCF2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ABCF2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ABCF2 Antibody (E-2): sc-390496
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ABCF2 CRISPR/Cas9 KO Plasmid (h) | sc-406271 | 20 µg | $397.00 |
Overview
ABCF2 (ATP-binding cassette subfamily F member 2) is a soluble ABC-family ATPase that lacks transmembrane domains and functions in the cytosol as a regulator of translation and ribosome-associated processes. It has been linked to control of protein synthesis under cellular stress and may influence proteostasis by modulating interactions with translation machinery. Through these roles, ABCF2 is relevant to pathways that shape cell growth, stress adaptation, and inflammatory signaling outputs downstream of altered translational control. Dysregulation of ABCF2 expression has been reported in cancer and other pathophysiology contexts where translational remodeling and stress-response programs are perturbed.
ABCF2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ABCF2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ABCF2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ABCF2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ABCF2 protein expression.
This CRISPR knockout system enables efficient generation of ABCF2-deficient cell models for investigation of ABCF2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ABCF2 exon(s) critical for ABCF2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ABCF2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ABCF2 CRISPR/Cas9 KO Plasmid (h) and ABCF2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ABCF2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ABCF2 HDR Plasmid (h) and ABCF2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ABCF2 homology arms to support homology-directed repair at defined ABCF2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.